Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.8094 USD Market Closed
Market Cap: 184.1m USD
Have any thoughts about
Vaxart Inc?
Write Note

P/E
Price to Earnings

-2.5
Current
-2.1
Median
21.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-2.5
=
Market Cap
184.1m USD
/
Net Income
-72.3m USD
All Countries
Close
Market Cap P/E
US
Vaxart Inc
NASDAQ:VXRT
184.1m USD -2.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -183 078.5
US
Abbvie Inc
NYSE:ABBV
315.4B USD 62.1
US
Amgen Inc
NASDAQ:AMGN
142B USD 33.6
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 881.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD -221.4
US
Epizyme Inc
F:EPE
94.1B EUR -466.7
AU
CSL Ltd
ASX:CSL
137.8B AUD 32.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 17.4
US
Seagen Inc
F:SGT
39.3B EUR -54
NL
argenx SE
XBRU:ARGX
38.4B EUR -350.4
Earnings Growth PEG
US
Vaxart Inc
NASDAQ:VXRT
Average P/E: 205.4
Negative Multiple: -2.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -183 078.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.1
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.6
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
881.5
21%
42
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -221.4
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -466.7 N/A N/A
AU
CSL Ltd
ASX:CSL
32.3
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -350.4 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-2.1
2-Years Forward
P/E
-2.1
3-Years Forward
P/E
-1.8